

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

| Accounting Title  | 2020/09/30       | 2019/12/31       | 2019/09/30       |
|---|------------------|------------------|------------------|
| <b>Balance Sheet</b>  |                  |                  |                  |
| <b>Current assets</b>   |                  |                  |                  |
| Cash and cash equivalents   | 217,905          | 193,671          | 275,017          |
| Current financial assets at amortised cost  | 1,200            | 84,760           | 107,500          |
| Current contract assets   | 86,579           | 22,667           | 14,881           |
| Accounts receivable, net  | 80,834           | 93,111           | 24,513           |
| Accounts receivable due from related parties, net   | 5,065            | 10,602           | 15,358           |
| Other receivables   | 7,547            | 1,829            | 15,421           |
| Current inventories   | 79,925           | 56,123           | 70,194           |
| Prepayments   | 36,290           | 24,242           | 29,571           |
| Other current assets  | 3,553            | 7,954            | 3,104            |
| <b>Total current assets</b>   | <b>518,898</b>   | <b>494,959</b>   | <b>555,559</b>   |
| <b>Non-current assets</b>   |                  |                  |                  |
| Non-current financial assets at fair value through other comprehensive income                             | 205,484          | 149,305          | 145,409          |
| Property, plant and equipment   | 622,228          | 545,077          | 541,049          |
| Right-of-use assets   | 54,911           | 47,762           | 51,839           |
| Intangible assets   | 63,093           | 74,850           | 78,920           |
| Deferred tax assets   | 84,493           | 79,710           | 78,114           |
| Other non-current assets  | 44,269           | 16,331           | 12,298           |
| <b>Total non-current assets</b>   | <b>1,074,478</b> | <b>913,035</b>   | <b>907,629</b>   |
| <b>Total assets</b>   | <b>1,593,376</b> | <b>1,407,994</b> | <b>1,463,188</b> |
| <b>Current liabilities</b>  |                  |                  |                  |
| Current contract liabilities  | 88,288           | 91,686           | 84,749           |
| Accounts payable  | 54,923           | 24,699           | 52,059           |
| Other payables  | 114,998          | 87,979           | 90,202           |
| Other payables to related parties   | 11               | 13,328           | 13,236           |
| Current tax liabilities   | 627              | 0                | 0                |
| Current lease liabilities   | 16,743           | 13,623           | 13,819           |
| Other current liabilities   | 1,204            | 600              | 827              |
| <b>Total current liabilities</b>  | <b>276,794</b>   | <b>231,915</b>   | <b>254,892</b>   |
| <b>Non-current liabilities</b>  |                  |                  |                  |
| Deferred tax liabilities  | 7,661            | 3,806            | 2,901            |
| Non-current lease liabilities   | 38,226           | 33,177           | 36,973           |
| Other non-current liabilities   | 36,918           | 37,143           | 30,359           |
| <b>Total non-current liabilities</b>  | <b>82,805</b>    | <b>74,126</b>    | <b>70,233</b>    |
| <b>Total liabilities</b>  | <b>359,599</b>   | <b>306,041</b>   | <b>325,125</b>   |
| <b>Share capital</b>  |                  |                  |                  |
| Ordinary share  | 1,279,545        | 1,279,545        | 1,279,545        |
| Advance receipts for share capital  | 9,681            | 0                | 0                |
| <b>Total Share Capital</b>  | <b>1,289,226</b> | <b>1,279,545</b> | <b>1,279,545</b> |
| <b>Capital surplus</b>  |                  |                  |                  |
| <b>Total capital surplus</b>  | <b>44,307</b>    | <b>260,908</b>   | <b>260,908</b>   |
| <b>Retained earnings</b>  |                  |                  |                  |
| Unappropriated retained earnings (accumulated deficit)  | -195,204         | -473,311         | -433,698         |
| <b>Total retained earnings</b>  | <b>-195,204</b>  | <b>-473,311</b>  | <b>-433,698</b>  |
| <b>Other equity interest</b>  |                  |                  |                  |
| Unrealised gains (losses) from financial assets measured at fair value through other comprehensive income | 95,448           | 34,811           | 31,308           |
| <b>Total other equity interest</b>  | <b>95,448</b>    | <b>34,811</b>    | <b>31,308</b>    |
| <b>Total equity</b>   | <b>1,233,777</b> | <b>1,101,953</b> | <b>1,138,063</b> |
| <b>Total liabilities and equity</b>   | <b>1,593,376</b> | <b>1,407,994</b> | <b>1,463,188</b> |
| Number of share capital awaiting retirement   | 0                | 0                | 0                |
| Equivalent issue shares of advance receipts for ordinary share  | 283,200          | 0                | 0                |
| Number of shares in entity held by entity and by its subsidiaries   | 0                | 0                | 0                |

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

| Accounting Title   | 2020/3rd | 2019/3rd | 2020/01/01 To 2020/09/30 | 2019/01/01 To 2019/09/30 |
|--|----------|----------|--------------------------|--------------------------|
| <b>Income Statement</b>  |          |          |                          |                          |
| Total operating revenue  | 148,315  | 78,060   | 487,148                  | 259,370                  |
| Total operating costs  | 129,925  | 67,399   | 331,874                  | 175,910                  |
| Gross profit (loss) from operations  | 18,390   | 10,661   | 155,274                  | 83,460                   |
| Gross profit (loss) from operations  | 18,390   | 10,661   | 155,274                  | 83,460                   |
| Operating expenses   |          |          |                          |                          |
| Selling expenses   | 12,037   | 5,527    | 35,615                   | 23,689                   |
| Administrative expenses  | 11,803   | 13,074   | 36,194                   | 31,244                   |
| Research and development expenses  | 7,887    | 86,816   | 37,111                   | 217,107                  |
| Impairment loss (impairment gain and reversal of impairment loss) determined in accordance with IFRS 9                     | 555      | 1,619    | 4,002                    | 1,972                    |
| Total operating expenses   | 32,282   | 107,036  | 112,922                  | 274,012                  |
| Net operating income (loss)  | -13,892  | -96,375  | 42,352                   | -190,552                 |
| Non-operating income and expenses  |          |          |                          |                          |
| Total interest income  | 56       | 1,278    | 1,380                    | 2,998                    |
| Total other income   | 974      | 1,786    | 3,486                    | 5,327                    |
| Other gains and losses, net  | -2,898   | -3,893   | -6,295                   | -1,733                   |
| Finance costs, net   | 454      | 491      | 1,639                    | 1,491                    |
| Total non-operating income and expenses  | -2,322   | -1,320   | -3,068                   | 5,101                    |
| Profit (loss) from continuing operations before tax  | -16,214  | -97,695  | 39,284                   | -185,451                 |
| Total tax expense (income)   | -2,504   | -4,647   | -4,051                   | -9,949                   |
| Profit (loss) from continuing operations   | -13,710  | -93,048  | 43,335                   | -175,502                 |
| Profit (loss)  | -13,710  | -93,048  | 43,335                   | -175,502                 |
| Other comprehensive income   |          |          |                          |                          |
| Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income | -1,524   | -23,944  | 77,864                   | 7,828                    |
| Income tax related to components of other comprehensive income that will not be reclassified to profit or loss             | -951     | -4,077   | 3,855                    | 2,901                    |
| Components of other comprehensive income that will not be reclassified to profit or loss                                   | -573     | -19,867  | 74,009                   | 4,927                    |
| Total other comprehensive income   | -573     | -19,867  | 74,009                   | 4,927                    |
| Total comprehensive income   | -14,283  | -112,915 | 117,344                  | -170,575                 |
| Basic earnings per share   |          |          |                          |                          |
| Total basic earnings per share   | -0.11    | -0.73    | 0.34                     | -1.40                    |
| Diluted earnings per share   |          |          |                          |                          |
| Total diluted earnings per share   | -0.11    | -0.73    | 0.34                     | -1.40                    |

Provided by: Mycenax Biotech Inc.

Financial year: Yearly

Unit: NT\$ thousand

| Accounting Title  | 2020/01/01To2020/09/30 | 2019/01/01To2019/09/30 |
|---|------------------------|------------------------|
| <b>Statements of Cash Flows</b>   |                        |                        |
| Cash flows from (used in) operating activities, indirect method                             |                        |                        |
| Profit (loss) from continuing operations before tax   | 39,284                 | -185,451               |
| Profit (loss) before tax  | 39,284                 | -185,451               |
| Depreciation expense  | 86,955                 | 81,450                 |
| Amortization expense  | 12,153                 | 10,206                 |
| Expected credit loss (gain) / Provision (reversal of provision) for bad debt expense        | 4,002                  | 1,972                  |
| Interest expense  | 1,639                  | 1,491                  |
| Interest income   | -1,380                 | -2,998                 |
| Share-based payments  | 4,799                  | 223                    |
| Loss (gain) on disposal of property, plan and equipment                                     | 2,365                  | 1,225                  |
| Impairment loss on non-financial assets   | -3,185                 | 2,133                  |
| Other adjustments to reconcile profit (loss)  | -1,139                 | 0                      |
| Total adjustments to reconcile profit (loss)  | 106,209                | 95,702                 |
| Decrease (increase) in contract assets  | -63,912                | 449                    |
| Decrease (increase) in accounts receivable  | 8,238                  | 27,602                 |
| Decrease (increase) in accounts receivable due from related parties                         | 5,587                  | -15,065                |
| Decrease (increase) in other receivable   | -5,803                 | 6,990                  |
| Decrease (increase) in inventories  | -20,617                | -11,910                |
| Decrease (increase) in prepayments  | -12,048                | -6,735                 |
| Adjustments for decrease (increase) in other current assets                                 | 4,002                  | -714                   |
| Total changes in operating assets   | -84,553                | 617                    |
| Increase (decrease) in contract liabilities   | -3,398                 | 36,232                 |
| Increase (decrease) in accounts payable   | 30,224                 | 12,172                 |
| Increase (decrease) in other payable  | 36,389                 | -13,955                |
| Increase (decrease) in other payable to related parties                                     | -217                   | 117                    |
| Adjustments for increase (decrease) in other current liabilities                            | 339                    | 491                    |
| Increase (decrease) in net defined benefit liability  | -29                    | -59                    |
| Total changes in operating liabilities  | 63,308                 | 34,998                 |
| Total changes in operating assets and liabilities   | -21,245                | 35,615                 |
| Total adjustments   | 84,964                 | 131,317                |
| Cash inflow (outflow) generated from operations   | 124,248                | -54,134                |
| Interest paid   | -1,002                 | -1,913                 |
| Income taxes refund (paid)  | 294                    | -415                   |
| Net cash flows from (used in) operating activities  | 123,540                | -56,462                |
| Cash flows from (used in) investing activities  |                        |                        |
| Proceeds from disposal of financial assets at fair value through other comprehensive income | 21,685                 | 0                      |
| Acquisition of financial assets at amortised cost   | 0                      | -18,901                |
| Proceeds from disposal of financial assets at amortised cost                                | 83,560                 | 0                      |
| Acquisition of property, plant and equipment  | -138,062               | -128,178               |
| Proceeds from disposal of property, plant and equipment                                     | 1,166                  | 0                      |
| Increase in refundable deposits   | -202                   | -274                   |
| Acquisition of intangible assets  | -396                   | -897                   |
| Decrease in other financial assets  | 0                      | 10,000                 |
| Increase in prepayments for business facilities   | -54,014                | -19,955                |
| Interest received   | 1,452                  | 2,984                  |
| Other investing activities  | -13,100                | -117,900               |
| Net cash flows from (used in) investing activities  | -97,911                | -273,121               |
| Cash flows from (used in) financing activities  |                        |                        |
| Payments of lease liabilities   | -11,076                | -12,545                |
| Proceeds from issuing shares  | 0                      | 401,400                |
| Exercise of employee share options  | 9,681                  | 0                      |
| Net cash flows from (used in) financing activities  | -1,395                 | 388,855                |
| Net increase (decrease) in cash and cash equivalents  | 24,234                 | 59,272                 |
| Cash and cash equivalents at beginning of period  | 193,671                | 215,745                |
| Cash and cash equivalents at end of period  | 217,905                | 275,017                |
| Cash and cash equivalents reported in the statement of financial position                   | 217,905                | 275,017                |

Provided by: Mycenax Biotech Inc.  
 Financial year: Yearly  
 Unit: NT\$ thousand

**2020/09/30 Statement of Stockholders' Equity**

Unit: NT\$ thousand

| Accounting Title  | Ordinary share | Advance receipts for share capital | Total share capital | Capital surplus | Unappropriated retained earnings (accumulated deficit) | Total retained earnings | Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income | Total other equity interest | Treasury shares | Total equity |
|---|----------------|------------------------------------|---------------------|-----------------|--|-------------------------|---|-----------------------------|-----------------|--------------|
| Equity at beginning of period   | 1,279,545      | 0                                  | 1,279,545           | 260,908         | -473,311   | -473,311                |   | 34,811                      | 34,811          | 1,101,953    |
| Capital surplus used to offset accumulated deficits   | 0              | 0                                  | 0                   | -221,400        | 221,400  | 221,400                 |   | 0                           | 0               | 0            |
| Profit (loss)   | 0              | 0                                  | 0                   | 0               | 43,335   | 43,335                  |   | 0                           | 0               | 43,335       |
| Other comprehensive income  | 0              | 0                                  | 0                   | 0               | 0  | 0                       |   | 74,009                      | 74,009          | 74,009       |
| Total comprehensive income  | 0              | 0                                  | 0                   | 0               | 43,335   | 43,335                  |   | 74,009                      | 74,009          | 117,344      |
| Share-based payments  | 0              | 0                                  | 0                   | 4,799           | 0  | 0                       |   | 0                           | 0               | 4,799        |
| Disposal of investments in equity instruments designated at fair value through other comprehensive income | 0              | 0                                  | 0                   | 0               | 13,372   | 13,372                  |   | -13,372                     | -13,372         | 0            |
| Others  | 0              | 9,681                              | 9,681               | 0               | 0  | 0                       |   | 0                           | 0               | 9,681        |
| Total increase (decrease) in equity   | 0              | 9,681                              | 9,681               | -216,601        | 278,107  | 278,107                 |   | 60,637                      | 60,637          | 131,824      |
| Equity at end of period   | 1,279,545      | 9,681                              | 1,289,226           | 44,307          | -195,204   | -195,204                |   | 95,448                      | 95,448          | 1,233,777    |

**2019/09/30 Statement of Stockholders' Equity**

Unit: NT\$ thousand

| Accounting Title                                    | Ordinary share | Total share capital | Capital surplus | Unappropriated retained earnings (accumulated deficit) | Total retained earnings | Unrealised gains (losses) on financial assets measured at fair value through other comprehensive income | Total other equity interest | Treasury shares | Total equity |
|---|----------------|---------------------|-----------------|--|-------------------------|---|-----------------------------|-----------------|--------------|
| Equity at beginning of period                       | 1,099,545      | 1,099,545           | 300,786         | -519,697   | -519,697                | 26,381  | 26,381                      |                 | 907,015      |
| Capital surplus used to offset accumulated deficits | 0              | 0                   | -261,501        | 261,501  | 261,501                 | 0   | 0                           |                 | 0            |
| Profit (loss)                                       | 0              | 0                   | 0               | -175,502   | -175,502                | 0   | 0                           |                 | -175,502     |
| Other comprehensive income                          | 0              | 0                   | 0               | 0  | 0                       | 4,927   | 4,927                       |                 | 4,927        |
| Total comprehensive income                          | 0              | 0                   | 0               | -175,502   | -175,502                | 4,927   | 4,927                       |                 | -170,575     |
| Issue of shares                                     | 180,000        | 180,000             | 221,400         | 0  | 0                       | 0   | 0                           |                 | 401,400      |
| Share-based payments                                | 0              | 0                   | 223             | 0  | 0                       | 0   | 0                           |                 | 223          |
| Total increase (decrease) in equity                 | 180,000        | 180,000             | -39,878         | 85,999   | 85,999                  | 4,927   | 4,927                       |                 | 231,048      |
| Equity at end of period                             | 1,279,545      | 1,279,545           | 260,908         | -433,698   | -433,698                | 31,308  | 31,308                      |                 | 1,138,063    |